leptospirosi
seriou
infect
diseas
caus
pathogen
strain
leptospira
spirochet
affect
human
also
anim
long
expect
find
effect
vaccin
prevent
leptospirosi
immun
high
risk
human
anim
although
leptospirosi
vaccin
obtain
vaccin
rel
unsuccess
clinic
applic
despit
decad
research
million
dollar
spent
review
recent
advanc
recombin
outer
membran
protein
omp
vaccin
lipopolysaccharid
lp
vaccin
inactiv
vaccin
attenu
vaccin
dna
vaccin
leptospirosi
review
comparison
vaccin
may
lead
develop
new
potenti
method
combat
leptospirosi
facilit
leptospirosi
vaccin
research
moreov
vaccin
ontolog
databas
built
scientist
work
leptospirosi
vaccin
start
tool
leptospirosi
widespread
diseas
caus
infect
spirochet
bacterium
leptospira
affect
almost
mammal
leptospirosi
initi
describ
weil
syndrom
predominantli
occup
diseas
affect
human
come
frequent
contact
rodent
pet
pollut
water
fig
infect
facilit
penetr
leptospir
mucosa
open
skin
gain
entri
skin
bacterium
caus
seriou
diseas
symptom
leptospirosi
extrem
broad
mening
pneumon
hepat
nephriti
pancreat
erythema
nodosum
death
ing
time
infect
case
dead
report
howev
mani
human
leptospirosi
case
might
misdiagnos
omit
due
poor
medic
care
inform
leptospira
pathogen
serovar
divid
serogroup
mani
differ
strain
small
antigen
differ
found
serovar
leptospir
evolv
way
escap
immun
defens
pathogen
leptospir
abl
transloc
cell
monolay
rate
significantli
greater
nonpathogen
leptospir
rapid
transloc
pathogen
leptospir
mammalian
cell
allow
bacteria
quickli
reach
bloodstream
dissemin
multipl
organ
virul
leptospir
rapidli
enter
kidney
fibroblast
induc
program
cell
death
thu
challeng
immunologist
develop
effect
safe
leptospirosi
vaccin
current
molecular
cellular
studi
leptospirosi
vaccin
focus
bacteri
motil
lipopolysaccharid
lpss
lipoprotein
outermembran
protein
omp
potenti
virul
factor
howev
still
lack
extens
knowledgebas
annot
leptospirosi
vaccin
scientist
work
field
leptospirosi
vaccin
inspir
us
investig
current
develop
leptospirosi
vaccin
construct
databas
leptospirosi
vaccin
incorpor
leptospirosi
vaccin
inform
bioinformat
use
microsoft
sql
server
technolog
intellig
algorithm
see
section
websit
classifi
leptospirosi
vaccin
recombin
protein
vaccin
lipopolysaccharid
lp
vaccin
inactiv
attenu
vaccin
dna
vaccin
review
current
advanc
leptospirosi
vaccin
research
sever
leptospir
outer
membran
protein
eg
recogn
leptospirosi
vaccin
candid
test
anim
model
vaccin
develop
kda
innermembran
protein
identifi
pathogen
leptospira
factor
involv
virul
found
among
pathogen
leptospir
nonpathogen
leptospir
locat
outer
membran
expos
cell
surfac
consid
candid
novel
vaccin
leptospirosi
hostinduc
immunogen
protein
pathogen
l
interrogan
although
protect
characterist
avail
believ
outer
membran
protein
might
suitabl
vaccin
candid
lipoprotein
import
protein
leptospir
protein
abund
outer
membran
attach
fatti
acid
difficulti
product
lipoprotein
heterolog
express
system
report
potenti
vaccin
howev
mani
lipoprotein
exampl
could
suitabl
vaccin
candid
identifi
target
natur
infect
leptospir
potenti
use
serodiagnosi
may
serv
target
vaccin
design
describ
surfac
membran
lipoprotein
produc
infect
conserv
among
pathogen
leptospira
speci
produc
lipoprotein
process
ctermin
form
moreov
lipoproteinlik
complex
glycolipoprotein
glp
suggest
vaccin
candid
glycolipoprotein
glp
extract
either
pathogen
l
interrogan
nonpathogen
l
biflexa
shown
induc
product
tumor
necrosi
factor
obvious
report
lipoprotein
glp
leptospirosi
vaccin
candid
hand
lipoprotein
found
suitabl
leptospirosi
vaccin
kda
leptospir
outer
membran
lipoprotein
synthes
vivo
product
protein
downregul
hostadapt
leptospir
suggest
involv
pathogenesi
entri
mammalian
host
virul
factor
major
target
vaccin
design
virul
factor
hemolysin
sphh
poreform
protein
sever
mammalian
cell
immun
serum
fulllength
hemolysin
effect
neutral
sphhmediat
hemolyt
cytotox
activ
sphh
requir
pore
format
mammalian
cell
membran
cytotox
activ
mammalian
cell
virul
factor
chpk
encod
l
interrogan
chp
locu
consist
two
gene
chpk
chpi
express
chpk
escherichia
coli
result
inhibit
bacteri
growth
coexpress
chpi
neutral
chpk
toxic
chp
locu
found
repres
pathogen
strain
l
interrogan
virul
factor
describ
flaa
flab
sphh
chpk
consid
candid
leptospirosi
vaccin
lig
protein
approv
vaccin
leptospira
anim
mani
recent
report
outer
membran
protein
lipoprotein
glp
newli
discov
virul
factor
flaa
flab
sphh
chpk
help
us
find
suitabl
vaccin
candid
genom
l
interrogan
serovar
icterohaemorrhagia
lai
l
interrogan
serovar
copenhageni
report
heterolog
express
leptospir
outer
membran
protein
omp
becam
possibl
open
new
possibl
vaccin
develop
basic
rout
largescal
screen
leptospirosi
vaccin
shown
fig
recombin
protein
vaccin
leptospirosi
use
clinic
applic
extens
test
requir
recombin
protein
vaccin
must
free
contamin
stabl
safe
easi
transport
store
found
lp
vaccin
may
serovarindepend
exampl
lp
vaccin
prepar
l
biflexa
serovar
patoc
effect
protect
hamster
l
interrogan
serovar
manila
case
protect
effect
strongli
depend
dose
administr
time
lp
vaccin
prepar
l
biflexa
serovar
patoc
howev
also
report
lp
vaccin
serovardepend
exampl
lp
vaccin
prepar
sever
differ
serovar
strain
could
induc
protect
immun
respons
gerbil
strain
differ
serovar
obvious
studi
requir
determin
whether
lp
vaccin
serovardepend
independ
lp
vaccin
serovarindepend
differ
anim
human
make
lp
vaccin
simpl
effici
pioneer
research
leptospir
lp
vaccin
report
immun
characterist
lpss
polysaccharid
ps
hamster
compar
hamster
immun
leptospir
lpss
largescal
screen
leptospirosi
vaccin
ps
fraction
l
interrogan
serovar
copenhageni
maximum
titer
observ
approxim
week
immun
protect
achiev
immun
littl
lp
ps
immun
characterist
lp
compar
ps
immunoconjug
ps
diphtheria
toxoid
dt
mice
vaccin
compound
maximum
agglutinin
titer
could
achiev
week
vaccin
lp
psdt
conjug
psdt
gave
antibodi
titer
least
time
higher
produc
respons
lp
titer
obtain
experi
antigen
serovar
pomona
higher
serovar
hardjo
protect
abil
lp
extract
compar
protein
extract
experi
leptospirosi
induc
gerbil
total
extract
induc
complet
protect
homolog
infect
partial
protect
heterolog
infect
lp
fraction
protect
homolog
heterolog
infect
wherea
protein
extract
caus
signific
protect
type
infect
moreov
immunogen
oligosaccharid
fraction
lp
l
interrogan
serovar
pomona
report
oligosaccharid
isol
endoglycosidas
h
digest
column
chromatographi
purif
conjug
diphtheria
toxoid
oligosaccharid
caus
product
signific
amount
protect
antibodi
sever
lipopolysaccharidelik
substanc
lsss
report
leptospira
antigen
lss
extract
l
interrogan
chloroformmethanolwat
solut
partial
purifi
silica
gel
column
chromatographi
antigen
exhibit
protect
activ
hamster
infect
lethal
dose
l
interrogan
moreov
ll
extract
l
interrogan
hot
phenolwat
method
could
enhanc
immunolog
respons
vivo
sinc
lpss
major
antigen
involv
serolog
respons
molecul
consid
candid
serodiagnosi
exampl
although
l
borgpetersenii
subtyp
hardjobovi
l
interrogan
subtyp
hardjoprajitno
belong
differ
speci
serolog
indistinguish
thu
classifi
serovar
hardjo
lpss
subtyp
ident
henc
lpss
use
leptospirosi
vaccin
also
antigen
serodiagnost
although
lpss
test
leptospirosi
vaccin
almost
year
promis
result
obtain
still
mani
problem
solv
other
detail
composit
structur
leptospir
lpss
determin
inactiv
attenu
vaccin
report
year
inactiv
attenu
leptospirosi
vaccin
success
test
cattl
dog
inactiv
leptospirosi
vaccin
also
test
human
volunt
sera
person
vaccin
bival
whole
cell
inactiv
vaccin
l
interrogan
serovar
hardjo
serovar
pomona
contain
igm
specif
serovar
although
leptospirosi
vaccin
licens
human
produc
cuba
sinc
inactiv
attenu
vaccin
still
acquir
consider
interest
especi
suitabl
veterinari
vaccin
dog
vaccin
twice
vaccin
infect
l
interrogan
follow
second
vaccin
high
rate
protect
l
interrogan
observ
durat
immun
least
effici
inactiv
vaccin
could
improv
adjuv
vaccin
frequenc
commerci
inactiv
leptospirosi
vaccin
adjuv
induc
poor
antibodi
product
cattl
preliminari
vaccin
howev
booster
vaccin
vaccin
caus
remark
immun
respons
hydrostat
pressuretr
leptospir
use
inactiv
vaccin
leptospir
inocul
rabbit
vaccin
immunogen
inactiv
vaccin
induc
strong
antigenspecif
prolif
respons
peripher
blood
mononuclear
cell
pbmc
vaccin
cattl
month
first
dose
vaccin
result
discuss
show
inactiv
attenu
vaccin
suitabl
leptospirosi
vaccin
howev
vaccin
caus
safeti
problem
dna
vaccin
use
differ
diseas
vaccin
sever
advantag
recombin
protein
vaccin
name
dna
vaccin
simpl
process
rout
low
price
easi
administr
properti
year
dna
vaccin
technolog
develop
interest
observ
practic
applic
surprisingli
two
leptospir
dna
vaccin
trial
report
dna
vaccin
encod
hemolysisassoci
protein
test
gerbil
partial
protect
infect
pathogen
strain
leptospira
achiev
anoth
exampl
use
dna
vaccin
contain
endoflagellin
gene
experi
guinea
pig
obvious
leptospirosi
dna
vaccin
need
extens
investig
valuabl
test
immun
characterist
multipl
leptospirosi
dna
vaccin
complex
anim
develop
leptospirosi
vaccin
possibl
construct
databas
leptospirosi
vaccin
construct
leptospirosi
vaccin
ontolog
databas
avail
websit
databas
present
inform
import
leptospirosi
vaccin
vaccin
databas
ontolog
valu
obtain
basi
experiment
result
particular
report
expert
evalu
believ
databas
may
help
scientist
work
leptospirosi
field
well
work
bioinformat
inform
vaccin
transmit
bioinformat
field
vaccin
classif
process
optim
predict
vaccin
effici
amino
acid
sequenc
composit
without
experi
anim
vaccin
administ
larg
number
healthi
human
anim
make
resist
diseas
therefor
vaccin
must
high
safeti
two
basic
type
leptospirosi
vaccin
avail
attenu
inactiv
leptospirosi
vaccin
howev
two
type
vaccin
reveal
signific
safeti
problem
attenu
vaccin
achiev
propag
microb
condit
differ
infect
host
hope
unfavor
growth
host
obvious
method
could
guarante
enough
safeti
requir
mani
test
ensur
safeti
safeti
still
remain
issu
ration
approach
attenu
microb
would
inactiv
leptospir
compon
gene
known
code
virul
factor
exampl
attenu
leptospir
vaccin
could
develop
elimin
leptospir
antigen
analog
inactiv
lp
biosynthet
loci
rfb
might
result
attenu
leptospir
strain
care
analysi
gene
code
virul
factor
leptospira
allow
us
construct
attenu
strain
leptospirosi
vaccin
inactiv
leptospirosi
vaccin
extens
investig
th
centuri
major
problem
concern
safeti
efficaci
appear
combin
attenu
inactiv
leptospirosi
vaccin
may
highli
effect
new
attenu
vaccin
design
basi
knowledg
sequenc
genom
virul
determin
pathogen
maxim
safeti
real
breakthrough
leptospirosi
vaccin
genet
technolog
allow
express
leptospir
gene
heterolog
organ
fact
mani
outer
membran
protein
obtain
candid
vaccin
advantag
product
recombin
vaccin
antigen
select
heterolog
host
organ
aris
simplic
cultiv
host
purif
recombin
protein
furthermor
recombin
protein
use
antigen
immunoassay
detect
leptospir
report
leptospirosi
vaccin
adjuv
immunogen
without
adjuv
thu
appear
research
requir
develop
novel
adjuv
leptospirosi
vaccin
like
recent
describ
bacteri
trna
adjuv
cdigmp
adjuv
increas
attent
devot
fact
infect
leptospir
natur
acquir
mucosa
administ
vaccin
mucos
rout
oral
rout
nasal
spray
topic
applic
skin
would
welcom
optim
formul
adjuv
dose
schedul
crucial
vaccin
efficaci
idea
produc
leptospir
antigen
protein
compon
edibl
plant
inde
feasibl
idea
combin
leptospirosi
vaccin
drug
cure
leptospirosi
interest
improv
qualiti
dna
vaccin
recombin
protein
vaccin
appear
import
practic
applic
moreov
believ
construct
web
servic
like
leptospirosi
vaccin
ontolog
databas
would
import
scientist
work
leptospirosi
vaccin
author
declar
compet
interest
author
contribut
content
articl
